Quanterix

The new SR-Plex system comes without integrated sample prep, making it less expensive and more amenable to non-protein work like nucleic acid assays.

The funding was led by T. Rowe Price and will be used by Quanterix to develop new instruments, expand the firm's assay menu, and other things. 

They demonstrated the applicability of the Simoa platform for nucleic acid detection, and miRNA detection in particular, as Quanterix prepares to launch a new system.

The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.

Researchers and companies move to develop blood-based tests for concussion, according to Scientific American.

Mark of a Concussion

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.

As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.   

The company will develop the assays for its single-molecule array technology and incorporate the markers into multiplex assays for research use in neurology.

Pages

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.